Cencora stock: A 25.36 P/ E gives Cencora stock a valuation anchor

Published on 10/19/2026 at 15:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The NYSE range was USD 244.82 to USD 377.54 on October 19, 2026. Cencora stock costs EUR 303.65 on October 19, 2026, with a 0.09 percent NYSE move.

Valuation and calendar facts

Cencora's P/E stood at 25.36 on October 19, 2026.
The NYSE range ran from USD 244.82 to USD 377.54 on October 19, 2026.
Cencora stock costs EUR 303.65 at Lang & Schwarz on October 19, 2026 at 3:38 p.m. CEST, with a 0.09 percent move on the NYSE.
Cencora's fiscal fourth-quarter results are scheduled for November 4, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora stock carried a price-to-earnings ratio of 25.36 on October 19, 2026, putting valuation ahead of the company's next scheduled earnings date. Cencora set November 4, 2026 for its fiscal fourth-quarter results. Cencora stock was trading at EUR 303.65 at Lang & Schwarz on October 19, 2026 at 3:38 p.m. CEST.

Range leaves room below the high

The NYSE quote was USD 341.21 at 9:55 a.m. ET on October 19, 2026, up 0.09 percent from the prior close of USD 340.92. The same session's 52-week range stretched from USD 244.82 to USD 377.54, leaving the stock 9.63 percent below its high and 39.37 percent above its low.

Cencora's market capitalization was USD 65.1 billion on October 19, 2026. Its average trading volume was 1,305,845 shares, while the session volume stood at 67,046 shares. The dividend yield was 1.00 percent.

November 4 sets the next date

The company has scheduled its fiscal fourth-quarter release before the New York Stock Exchange open on November 4, 2026, with an 8:30 a.m. ET conference call. The date gives the valuation a defined near-term event without changing the price picture described above.

For context, Cencora operates in healthcare distribution, while its United States peers McKesson and Cardinal Health provide a useful same-day comparison. Cencora's lower P/E than both peers places the valuation metric in a clear middle position within this small group.

Comparison with peers

The following figures are as of October 19, 2026.

Cencora Inc.: plus 0.09 percent, P/E 25.36, market capitalization USD 65.1 billion

McKesson Corporation (NYSE, USD): plus 0.20 percent, P/E 26.91, market capitalization USD 117.4 billion

Cardinal Health, Inc. (NYSE, USD): minus 0.53 percent, P/E 35.00, market capitalization USD 58.5 billion

Price and the next checkpoint

Cencora stock was trading at EUR 303.65 at Lang & Schwarz on October 19, 2026 at 3:38 p.m. CEST. On the NYSE, the stock stood at USD 341.21, 0.09 percent above its prior close of USD 340.92.

The further course of trading is shown by the continuously updated real-time quote of Cencora stock.